Physician profile
Benjamin W Friedman
NPI 1205906484
$9,768.95
in general payments reported to CMS, 2019-2025
11 companies · $304 in 2025
The $304 reported for 2025 was more than what 89% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.00 · 2021: $7,700 · 2022: $1,715 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $7,700.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $1,590.00 | 2022 | |
| Abbvie INC. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $98.62 | 2025 | Tremfya |
| Lilly USA, LLC | $78.88 | 2025 | Taltz |
| Allergan, INC. | $50.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $38.93 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $28.42 | 2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.76 | 2025 | |
| Almatica Pharma LLC | $19.43 | 2025 | Teriparatide |
| Acadia Pharmaceuticals INC | $14.91 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.